Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Business Wire•06/08/2026•16:02 ET

Whiz Insights

* JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts

Get started

Create a free account to read the full story.

Already have an account? Log in